Lexaria Bioscience (LEXX) EPS (Basic) Growth (5y) (2019 - 2026)
Lexaria Bioscience (LEXX) EPS (Basic) Growth (5y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.70 Bn | 131.85 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.75 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.36 Bn | 60.18 Bn | 1.37 Bn |
| 4 | Moderna | 59.15 Bn | 54.01 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.88 Bn | 28.57 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.14 Bn | 9.75 Bn | 668.28 Mn |
| 8 | Insmed | 27.59 Bn | 26.43 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.48 Bn | - |
| 10 | Lexaria Bioscience | 10.17 Mn | 6.55 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | 18.33% |
| Feb 28, 2026 | 25.53% |
| Nov 30, 2025 | 21.04% |
| Aug 31, 2025 | 26.13% |
| May 31, 2025 | 23.56% |
| Feb 28, 2025 | 23.53% |
| Nov 30, 2024 | 31.81% |
| Aug 31, 2024 | 22.60% |
| May 31, 2024 | 18.10% |
| Feb 29, 2024 | 16.28% |
| Nov 30, 2023 | 19.92% |
| Aug 31, 2023 | 18.63% |
| May 31, 2023 | 17.69% |
| Feb 28, 2023 | 18.86% |
| Nov 30, 2022 | -3.13% |
| Aug 31, 2022 | 6.59% |
| May 31, 2022 | -19.00% |
| Feb 28, 2022 | 24.55% |
| Nov 30, 2021 | -8.68% |
| Aug 31, 2021 | -4.51% |